BCL2L11 and lymphoma: Such lymphoma derived MYC mutants (T58A, P57S) have been shown to increase the half-life of MYC protein from 30 to 110 min, and also confer increased transforming capacity, but are defective in promoting apoptosis due to failure to activate BIM [44, 45, 47].